# OnCo record pasireotide (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/pasireotide/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "pasireotide" ;
  schema:name "Pasireotide"@en ;
  schema:alternateName "SOM230"@en, "Signifor / Signifor LAR" ;
  schema:description "Pasireotide is a second-generation somatostatin analogue that hits more receptor types than octreotide. It is approved for Cushing's disease and acromegaly caused by pituitary tumours when surgery has not cured them, at the cost of frequent high blood sugar."@en ;
  schema:url <https://onco.cc/drugs/pasireotide/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Pasireotide> ;
  schema:citation <https://en.wikipedia.org/wiki/Pasireotide> ;
  onco:status "approved" ;
  onco:tag "subtype-drugs-wave" ;
  onco:modality "Multireceptor somatostatin analogue (subcutaneous or monthly depot)" ;
  onco:approval "US 2012: Cushing's disease when pituitary surgery is not an option or has not been curative", "US 2014: Acromegaly inadequately controlled by surgery or for whom surgery is not an option (long-acting depot)" ;
  onco:related <https://onco.cc/drugs/octreotide-lanreotide/>, <https://onco.cc/drugs/everolimus/> ;
  onco:cancers <https://onco.cc/cancers/pituitary-tumours/>, <https://onco.cc/cancers/lung-net/> ;
  onco:targets <https://onco.cc/targets/sstr2/> ;
  onco:companies <https://onco.cc/companies/recordati/> .